Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Benitec Biopharma Inc.BNTC · Entity 5596 | Director | December 01, 2025 | December 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Benitec Biopharma Inc.
Report date December 01, 2025 · Filed December 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2035-12-01 | Direct | 35,000 |
Reported balance
After 2025-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-01 · Grant · Acquired 35,000 · Balance 35,000 F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2025 Filed Dec 3, 2025 16:17 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001012975-25-000848 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-12-01 F1 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 17:24 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001062993-24-020470 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 19:56 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001062993-23-022119 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 19:21 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 12,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001062993-22-023658 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 18:55 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001062993-21-012694 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-12-08 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:56 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 23,601 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001062993-20-006259 · form4.xml · derivative · entry 1 Francis Peter · CIK 0001808850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,601 Underlying: Common Stock · 23,601 shares Expires 2030-12-09 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer???s next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.